Gerhard Glatting Email and Phone Number

I lead the Medical Radiation Physics group at Ulm University's Department of Nuclear Medicine, where our research is dedicated to advancing the field of Molecular Radiotherapy, Targeted Radionuclide Therapy, and Radiopharmaceutical Therapy. Our primary focus is optimising these therapies by applying physiologically based pharmacokinetic (PBPK) and pharmacodynamic (PD) modelling. These sophisticated models enable us to tailor treatments to individual patients, embodying the essence of precision medicine.In pursuing personalised medicine, we employ quantitative systems biology and pharmacology, extending our investigations to encompass the entire patient population. Using in silico clinical trials, we formulate hypotheses that guide future clinical trials, fostering innovation in treatment strategies. Furthermore, our commitment extends beyond theoretical models, incorporating in vitro and preclinical findings to seamlessly translate advancements from the laboratory to clinical practice.Our work contributes to the progression of personalised treatment and yields improvements in Radiation Protection. This positive outcome directly results from our meticulous personalised treatment planning, adding a valuable dimension to our research.Another pivotal area of our research involves Non-Linear Mixed-Effects (NLME) modelling, focusing on Single-Time-Point (STP) dosimetry. This facet of our work underscores our dedication to advancing the precision and efficacy of ionising radiation-based therapies.References: https://pubmed.ncbi.nlm.nih.gov/?term=Glatting-G&sort=date